Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis Journal Article

   


Authors: Li, H.; Chiang, C. L.; Kwak, K. J.; Wang, X.; Doddi, S.; Ramanathan, L. V.; Cho, S. M.; Hou, Y. C.; Cheng, T. S.; Mo, X.; Chang, Y. S.; Chang, H. L.; Cheng, W.; Tsai, W. N.; Nguyen, L. T. H.; Pan, J.; Ma, Y.; Rima, X. Y.; Zhang, J.; Reategui, E.; Chu, Y. S.; Chang, P. M. H.; Chang, P. H.; Huang, C. Y. F.; Wang, C. H.; Shan, Y. S.; Li, C. P.; Fleisher, M.; Lee, L. J.
Article Title: Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis
Abstract: Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late-stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression of mRNAs and their corresponding proteins in extracellular vesicles (EVs) circulating in blood. Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings demonstrate that glypican 1 (GPC1) mRNA expression in the exosomes-rich (Exo) EV subpopulation and GPC1 membrane protein (mProtein) expression in the microvesicles-rich (MV) EV subpopulation, particularly the tumor associated microvesicles (tMV), served as a viable biomarker for PDAC. A combined analysis effectively discriminated early-stage PDAC patients from benign pancreatic diseases and healthy donors in sizable clinical from multiple hospitals. Furthermore, among late-stage PDAC patients undergoing chemotherapy, lower GPC1 tMV-mProtein and Exo-mRNA expression before treatment correlated significantly with prolonged overall survival. These findings underscore the potential of vesicular GPC1 expression for early PDAC screenings and chemotherapy prognosis. © 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Keywords: genetics; pancreatic neoplasms; chemotherapy; proteins; biomarkers; metabolism; carcinoma, pancreatic ductal; tumor marker; messenger rna; tumors; rna, messenger; diagnosis; biochips; pancreas tumor; pancreatic ducts; nanoparticles; liposomes; extracellular; exosome; exosomes; pancreatic ductal carcinoma; microvesicles; humans; prognosis; human; glypican; extracellular vesicles; glypicans; biomarkers, tumor; glypican 1 mrna in exosomes and protein in tumor-associated microvesicles as a dual biomarker; immune lipoplex nanoparticle biochip assay; pdac screening and chemotherapy prognosis; single extracellular vesicle analysis; gpc1 protein, human; glypican 1 mrna in exosome and protein in tumor-associated microvesicle as a dual biomarker; late stage; lipoplexes; pancreatic duct adenocarcinoma screening and chemotherapy prognose; single extracellular vesicle analyse
Journal Title: Advanced Science
Volume: 11
Issue: 11
ISSN: 2198-3844
Publisher: Wiley-VCH Verlag GmbH & Co. KGaA  
Date Published: 2024-03-01
Start Page: 2306373
Language: English
DOI: 10.1002/advs.202306373
PUBMED: 38204202
PROVIDER: scopus
PMCID: PMC10953589
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181893446&doi=10.1002%2fadvs.202306373&partnerID=40&md5=17d3062859a23d867be059d3171520e1
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Martin Fleisher
    312 Fleisher
  2. Lakshmi Vulimiri Ramanathan
    77 Ramanathan
  3. Sun Min Cho
    11 Cho
  4. Sital Doddi
    10 Doddi
Related MSK Work